Insmed rallies strongly following Piper Jaffray PT hike

Piper Jaffray raises its price target for Insmed (INSM) to $45 from $34, well above the company's close of $16.61 on Friday.

Piper's move comes a week after UBS and Wedbush downgraded Insmed and slashed their PTs to $7 from $18.

Insmed's shares tumbled following the downgrades but are +10.2% at $18.30 premarket.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs